Table 1

Respondents

Patients (n=282)General public (n=250)
Age (SD)65.0 (8.3)46.0 (16.7)
Male (%)5755
Education
 Low (%)4813.0
 Middle (%)3734.8
 High (%)1552.2
Current smoker32%
Ex-smoker62%
Never smoked6%
­
COPD diagnosis (%)1008.3
FEV1, as % of predicted (SD)60 (18)
GOLD 1*12%
GOLD 2*54%
GOLD 3*31%
GOLD 4*3%
Any exacerbations in year before study49.8%
Number of exacerbations in in year before study (SD)0.89 (1.15)
SGRQ (SD)37 (19)
EQ-5D† (SD)0.84 (0.16)
­
Any comorbidity‡31%
Asthma5%
Diabetes mellitus12%
Heart failure6%
Osteoporosis4%
Depression4%
Malignity2%
Other comorbidity13%
­
Treated in general practitioner practice61%
Treated by pulmonologist39%
  • *Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage (1: forced expiratory volume in 1 s (FEV1) >80% of predicted, 2: FEV150%–80% of predicted, 3: FEV130%–50% of predicted, 4: <30% of predicted).

  • EQ-5D, health-related quality of life (0=dead, 1=perfect health).

  • ‡Comorbidities were only recorded for patients who were randomised to the intervention group in the ABC trial (n=136).

  • COPD, chronic obstructive pulmonary disease; SGRQ, Saint George’s Respiratory Questionnaire (0–100, higher is worse).